The ETANTR (ETMR) Pilot Program: $170,000 annually

Help us unlock the key to a cure for ETMR

Embryonal tumors with abundant neuropil and true rosettes (ETANTR) is a rare category of brain tumors of children that generally occurs in the cerebrum (but not exclusively) and has a median survival of only 9-13 months. Due to the severe nature of this tumor and the scarcity of preclinical resources necessary to make drug screens possible, our consortium will start by developing cell lines and mouse models and then create shareable central resource(biorepository) for cell lines and mouse models. Then, using robotic drug screening and computational approaches to prioritize single agents and drug combinations, we will discover new, effective therapeutics (drugs) to treat ETMR.